Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07667972
Active, not recruiting Not applicable

Microfocused Ultrasound for Facial Pigmentary Diseases and Rosacea

NCT07667972 · tracked via the Priya Life Science China tracker
Sponsor
Xiangya Hospital of Central South University
Phase
Not applicable
Started
2025-10-01
Last updated
2026-06-30

Condition(s) studied

MelasmaRosaceaPeriorbital HyperpigmentationMelanosisLichen Planus Pigmentosus

Investigational drug(s) / intervention(s)

Microfocused Ultrasound TreatmentSham Microfocused Ultrasound Stimulation

Microfocused Ultrasound Treatment: Active microfocused ultrasound treatment will be administered using an ultrasound therapy device. Treatment parameters are planned as power 3.76 to 5.12 W and frequency 8 Hz. Each treatment session will stop when the preset treatment endpoint. Treatment will be performed once monthly for 6 months.

Sham Microfocused Ultrasound Stimulation: Sham stimulation will use the same procedure as active microfocused ultrasound treatment, including ultrasound coupling gel, probe contact, treatment environment, and treatment duration, but will not deliver effective therapeutic ultrasound energy.

Study summary

This clinical study will evaluate the efficacy and safety of microfocused ultrasound treatment in patients with facial pigmentary diseases and rosacea.

The study includes two independent disease cohorts: a facial pigmentary disease cohort and a rosacea cohort. Participants in each cohort will be randomly assigned to receive either active microfocused ultrasound treatment or sham stimulation. Sham stimulation will follow the same treatment procedure as active treatment but will not deliver effective therapeutic ultrasound energy.

Participants will receive one treatment session per month for 6 months and will be followed for up to 12 months. The study will assess changes in clinical severity scores, digital skin imaging parameters, patient-reported symptoms, quality of life, and safety outcomes, including adverse events.

Eligibility

Sex
ALL
Min age
20 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: 1. Male or female participants aged 20 to 60 years. 2. Diagnosed by the investigator as having facial pigmentary disease or rosacea eligible for this study. 3. Participants with rosacea must meet the diagnostic criteria of the Chinese Guideline for the Diagnosis and Treatment of Rosacea (2021 edition). 4. Participants with facial pigmentary diseases must be diagnosed by two dermatologists with associate senior professional title or above, based on clinical manifestations and, when necessary, auxiliary examinations such as Wood's lamp examination, dermoscopy, or skin histopathology. Eligible pigmentary diseases may include melasma, periorbital hyperpigmentation, melanosis, lichen planus pigmentosus, or other facial pigmentary diseases considered suitable for this study. 5. The skin lesions are suitable for microfocused ultrasound treatment and follow-up assessment. 6. Able to comply with study treatment, follow-up visits, photography, and related assessments during the study. 7. Able to understand the study procedures, voluntarily participate in the study, and sign written informed consent. Exclusion Criteria: 1. Pregnant or lactating women, or women planning to become pregnant during the study period. 2. Known allergy to ultrasound coupling gel or any of its excipients. 3. Presence of other obvious active inflammatory skin diseases, infectious skin diseases, or other facial skin conditions that may affect efficacy evaluation, apart from the target disease of this study. 4. Use within 1 month before screening of topical medications or procedures that may affect study evaluation, including but not limited to corticosteroids, calcineurin inhibitors, depigmenting agents, or energy-based treatments. 5. Severe cardiac, hepatic, renal, or other important organ dysfunction, or other severe systemic diseases that, in the investigator's judgment, may affect the safety or efficacy evaluation of this study. 6. Participation in another clinical trial within 30 days before screening. 7. History of prolonged intense sun exposure within 1 month before screening, or expected inability to avoid significant sun exposure or outdoor exposure during the study period, which may affect study evaluation. 8. Any other condition that, in the investigator's judgment, makes the participant unsuitable for this study.

Primary outcome measure(s)

  • Change From Baseline in Melasma Area and Severity Index-Based Pigment Area and Severity Score at Month 6 — Baseline to Month 6
    Change from baseline to Month 6 in the Melasma Area and Severity Index (MASI)-based pigment area and severity score in the pigmentary disease cohort. The score assesses lesion area, darkness, and homogeneity across facial regions. Total scores range from 0 to 48, with higher scores indicating more severe pigmentation.
  • Change From Baseline in Clinician's Erythema Assessment Score at Month 6 — Baseline to Month 6
    Change from baseline to Month 6 in the Clinician's Erythema Assessment (CEA) score in the rosacea cohort. The CEA score ranges from 0 to 4, where 0 indicates clear or no erythema and 4 indicates severe erythema. Higher scores indicate more severe erythema.

Trial sites (1)

FacilityCityRegionStatus
Xiangya Hospital, Central South University Changsha Hunan

More Xiangya Hospital of Central South University trials in China

Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis: Recruiting
Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST Recruiting
RET-Targeted Molecular Imaging Probes in Prostate Cancer Active, not recruiting
Chinese ET Registry (CETR) Recruiting
Preventive Effectiveness of Primary Care Physician-led CGM-supported Comprehensive Intervention on Cardio-metabolic-immune Diseases in Community Patients With Type 2 Diabetes (Community Diabetes Control Project) Starting soon

Other trials for the same condition

Acupuncture for Refractory Rosacea: A Study on Its Effectiveness and Safety Recruiting
Clinical Evaluation and Study of the Efficacy of a Centella Asiatica-Infused Facial Mask on Discosmetic Dermatosis Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07667972 on ClinicalTrials.gov ↗ ← All trials in China